Petros director granted 375,000 restricted shares

WALKER WAYNE REMELL reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

WALKER WAYNE REMELL reported acquisition or exercise transactions in this Form 4 filing.

Petros Pharmaceuticals director Wayne Remell Walker received an equity grant of company stock. He was awarded 375,000 restricted shares of Petros Pharmaceuticals common stock at no cash cost. According to the terms, 50% of these shares vested on the grant date and the remaining 50% will vest six months later if he is still providing services to the company at that time. Following this grant, he directly holds a total of 881,333 common shares.

Insider Trade Summary

Grant/Award: 375,000 shares

Grant/Award 1 txn

Insider WALKER WAYNE REMELL

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	375,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 881,333 shares (Direct)

Footnotes (1)

1. F1. Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date.

Key Figures

Restricted shares granted: 375,000 shares Grant price per share: $0.0000 per share Shares held after grant: 881,333 shares +2 more

5 metrics

Restricted shares granted 375,000 shares Grant of restricted common stock

Grant price per share $0.0000 per share Equity compensation, no cash cost

Shares held after grant 881,333 shares Total direct holdings following transaction

Immediate vesting portion 50% Vested on grant date

Deferred vesting portion 50% Vests six months after grant if services continue

Key Terms

restricted shares, vested, par value

3 terms

restricted shares financial

"Represents restricted shares ("Shares") of common stock, par value $0.0001 per share"

Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.

vested financial

"50% of the Shares vested on the date of grant and the remaining 50% will vest"

par value financial

"common stock, par value $0.0001 per share, of the Issuer"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the Petros Pharmaceuticals (PTPI) Form 4 report for Wayne Remell Walker?

The Form 4 shows Wayne Remell Walker received 375,000 restricted shares. These Petros Pharmaceuticals common shares were granted at no cash cost as equity compensation, increasing his direct holdings to 881,333 shares after the transaction.

How many PTPI shares does Wayne Remell Walker hold after this grant?

After the grant, Wayne Remell Walker directly holds 881,333 PTPI shares. This total reflects the addition of 375,000 restricted shares of Petros Pharmaceuticals common stock reported in the Form 4 filing.

What are the vesting terms of Wayne Remell Walker’s restricted PTPI shares?

The 375,000 restricted PTPI shares vest in two equal installments. Half vested on the grant date, and the remaining 50% vest six months later, if he continues providing services to Petros Pharmaceuticals on that vesting date.

Was cash paid for Wayne Remell Walker’s new Petros Pharmaceuticals shares?

No cash was paid for these Petros Pharmaceuticals shares. The Form 4 lists a price per share of $0.0000, indicating the 375,000 restricted shares were granted as equity compensation rather than purchased in the open market.

What type of security did Wayne Remell Walker receive from Petros Pharmaceuticals (PTPI)?

He received restricted shares of Petros Pharmaceuticals common stock. The Form 4 describes these as restricted shares of common stock, par value $0.0001 per share, subject to a two-stage vesting schedule over six months.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/08/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WALKER WAYNE REMELL

(Last) (First) (Middle)

C/O PETROS PHARMACEUTICALS, INC.

1185 AVENUE OF THE AMERICAS, 3RD FLOOR

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Petros Pharmaceuticals, Inc. [ PTPI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/05/2026		A		375,000(1)	A	$0(1)	881,333	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date.

	/s/ Wayne Walker	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)